Janus kinase inhibitors – a role for the treatment of cutaneous T-cell lymphomas?
Despite increases in prevalence, many cutaneous T-cell lymphoma (CTCL) patients still lack effective and safe therapies for their disease. The most prevalent subtype, mycosis fungoides is usually managed with skin directed treatments in early stages, while advanced stages are often targeted with sys...
Furkejuvvon:
| Váldodahkkit: | , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Frontiers Media S.A.
2025-08-01
|
| Ráidu: | Oncology Reviews |
| Fáttát: | |
| Liŋkkat: | https://www.frontiersin.org/articles/10.3389/or.2025.1482866/full |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|